RxDoctor Payments Data

Howard Edington, MD

Plastic and Reconstructive Surgery · Pittsburgh, PANPI 1568435592

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,508 of the $3,325 with a category attached, or 75.4%. Sanofi accounts for 75.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $2,561 and has fallen 91.2% since, to $225 in 2025.

$3,325in general payments, 2019–2025

Across 19 payments — averaging $175.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$3K
  • E.r. Squibb & Sons, L.L.C.$546
  • Novartis$129
  • AbbVie$49
  • Lilly USA, LLC$23
  • Integra Lifesciences Corporation$22
  • plus $48 from 3 others
$50,290in research payments, 2019–2025

Across 2 payments — averaging $25,145 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$50K

What the payments were for

  • Consulting fees$2,50875%
  • Food & beverage$81725%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,325 in reported general payments places this provider in the 65th percentile of 108 plastic and reconstructive surgery providers in Pennsylvania.

See all plastic and reconstructive surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$101,901
Medicare patients
264
Services billed
634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Imiquimod37$487
Cephalexin119$391
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen86$226
Clindamycin Hcl15$43

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →